Sandoz Reveals Aflibercept Program

Kicks Off Phase III Trials For Biosimilar Version Of Eylea

 
• By Dave Wallace

Sandoz has revealed late-stage clinical development plans for an aflibercept biosimilar, setting out details of a Phase III trial for the proposed Eylea rival.

Eye Scan Data
Sandoz is enrolling patients for an aflibercept trial • Source: Alamy

More from Biosimilars

More from Products